The Medicine Forum
Volume 16

Article 8

2015

Eculizumab for Gemcitabine-Induced Hemolytic Uremic
Syndrome: A Novel Therapy for an Emerging Condition
Raphael Karkowsky, MD
Thomas Jefferson University, Raphael.karkowsky@jefferson.edu

Kinjal Parikh, MD
Thomas Jefferson University, Kinjal.parikh@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/tmf
Part of the Medicine and Health Sciences Commons

Let us know how access to this document benefits you
Recommended Citation
Karkowsky, MD, Raphael and Parikh, MD, Kinjal (2015) "Eculizumab for Gemcitabine-Induced Hemolytic
Uremic Syndrome: A Novel Therapy for an Emerging Condition," The Medicine Forum: Vol. 16 , Article 8.
DOI: https://doi.org/10.29046/TMF.016.1.007
Available at: https://jdc.jefferson.edu/tmf/vol16/iss1/8

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in The Medicine Forum by an authorized administrator of the Jefferson Digital Commons.
For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Karkowsky, MD and Parikh, MD: Eculizumab for Gemcitabine-Induced Hemolytic Uremic Syndrome
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Emerging Condition
Raphael Karkowsky, MD and Kinjal Parikh, MD

Figure 1. Microscopic appearance of peripheral blood smear from
patient (×100), showing increased schistocytes, echinocytes, and
acanthocytes

Figure 2. Microscopic appearance of bone marrow biopsy from
patient (×20), showing hypercellular bone marrow with trilineage
hematopoiesis and no evidence of dysplasia or metastatic disease

Introduction

of 420 IU/L (reference range 125-240 IU/L), undetectable
haptoglobin, and the presence of schistocytes on the
peripheral smear (see Figure 1). Creatinine was elevated
to 2.8 mg/dL (reference range 0.7-1.4 mg/dL) and an
ADAMTS-13 (A disintegrin and metalloproteinase with a
thromboSpondin type 1 motif, member 13) returned as
normal. The patient was diagnosed with gemcitabineinduced aHUS. Gemcitabine was discontinued, and
the patient was started on steroids. Two weeks later,
he presented with generalized tonic-clonic seizures,
uncontrolled hypertension, and worsening renal failure.
His labs on admission showed continued hemolysis and
thrombocytopenia. In light of the patient’s poor response
to steroids, the decision was made to start eculizumab.

Atypical hemolytic uremic syndrome (aHUS), a
thrombotic microangiopathy (TMA), is a disease
characterized by hemolytic anemia, thrombocytopenia,
and renal impairment. Gemcitabine, a commonly used
chemotherapy, is emerging as a cause of aHUS. Although
rare, the morbidity and mortality can be significant.
Few studies have explored the use of eculizumab, an
anti-C5 monoclonal antibody as a potential therapy for
gemcitabine-induced aHUS.

Case Presentation
A 45 year old Caucasian male with metastatic urothelial
carcinoma was started on weekly gemcitabine (1000
mg/m2 per dose) to treat recurrent disease. During his
seventh cycle, he was hospitalized for hypertension,
acute kidney injury, and anemia. Laboratory data at
that time revealed a hemoglobin of 6.2 g/dL (reference
range 14.0-17.0 g/dL) and a platelet count of 70 x 109/L
(reference range 140-400x 10 9/L). Hemolysis was
suggested by an elevated lactate dehydrogenase (LDH)
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Differential Diagnosis
Gemcitabine-induced aHUS is often a difficult diagnosis
to make. In this case, it was distinguished from thrombotic
thrombocytopenic purpura (TTP) by normal levels of
ADAMTS-13. Furthermore, normal coagulation studies
and the lack of bleeding made disseminated intravascular
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coagulation unlikely. Bone marrow biopsy showed
trilineage, hypercellular hematopoiesis, suggesting
peripheral destruction rather than myelosuppression
from chemotherapy (see Figure 2). Idiopathic thrombocytopenic purpura was a less likely diagnosis, as the
presence of schistocytes suggested microangiopathy.

Outcome and Follow-up
The patient was started on eculizumab and received a
course of six doses. His treatment was complicated by
a multifocal pneumonia that developed four days after
receiving his second dose. His labs two months after
starting treatment showed an improved platelet count
of 118 x 109/L. Although he remained anemic, his labs
did not show evidence of further hemolysis (see figure
3). The patient’s creatinine remained elevated at 6.2 mg/
dL, and he was started on renal replacement therapy
(RRT). The patient died three months after initiation of
eculizumab therapy secondary to complications of his
underlying malignancy.

Discussion
The vast majority of HUS are preceded by a bout of
infectious diarrhea, usually due to Escheria coli; 90% of
cases are not, and are therefore termed atypical.1 This
atypical form of HUS is associated with factors such as
human immunodeficiency virus infection, malignancy,
organ transplantation, pregnancy, or medications,
including anti-neoplastic drugs.1,2 Recently, gemcitabine,
a 2`,2`-difluorodeoxycytidine, has surfaced as a cause
of atypical HUS. The incidence of gemcitabine-induced
aHUS ranges from 0.015 to 1.4%2 per current case series
reviews.
Pathologically, aHUS is identical to the typical form.
Histology generally shows arteriole and capillary
thickening, a swollen endothelium, and proteinaceous
deposits in the subendothelium. A blood smear will
typically show schistocytes. The kidneys are most
commonly involved, but the brain, lung, pancreas,
and gastrointestinal tract may be affected as well.
Dysregulation of the alternative complement cascade
leads to the formation of the final membrane-attack
complex (MAC) and subsequent endothelial injury,
which plays a pivotal role.1
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Figure 3. Chart Showing response to eculizumab treatment in
gemcitabine-induced thrombotic microangiopathy. Red arrows
represent eculuzimab administration and blue arrows represent
gemcitabine administration.

The most agreed upon treatment for gemcitabineinduced aHUS remains discontinuation of the drug.
Other therapies, such as therapeutic plasma exchange
(TPE), demonstrate less reliable effectiveness, as shown
in a recent meta-analysis by Gore and colleagues, which
concluded that the use of TPE is not associated with
an improved rate of recovery.8 Recent case reports
have also suggested a potential role for splenectomy8 or
rituximab.7 Novel therapies such as Complement Factor
H, a regulatory protein in the alternative complement
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cascade, is currently being studied as a treatment for
patients suffering from aHUS who are deficient in this
protein.1
The safety of eculizumab is still being determined. In
this case, the patient developed multifocal pneumonia
just days after receiving his second dose of eculizumab.
Inhibition of MAC formation by eculizumab reduces
defense against encapsulated organisms, specifically
those that cause pneumonia.10 Therefore, it is reasonable
to suspect, that eculizumab may have served as a risk
factor in our patient’s development of this complication.
Only a few studies have investigated the treatment of
gemcitabine-induced HUS with eculizumab. Similar
to the studies by Starck and colleagues and Legendre
and colleagues, this case study highlights eculizumab’s
effectiveness in improving microangiopathy and the
resultant thrombocytopenia and hemolysis in aHUS.
Those studies, although promising, were somewhat
confounded by prior use of TPE, which was not true in
our case. Lohr and colleagues’ case series, seemed to
suggest that eculizumab is an effective therapy for the
kidney damage sustained in aHUS. In our case study,
however, the patient did not demonstrate the same
improvement in kidney function, and his kidney disease
ultimately progressed to the point of needing RRT. The
role of eculuzimab in treating aHUS and its efficacy is
still being defined.

Key Points
The above case demonstrates eculizumab’s partial
effectiveness in treating the microangiopathy in
gemcitabine-induced aHUS. Although the patient
demonstrated recovery in platelet count and resolution
of his hemolysis, he showed only limited improvement
in renal function. Moreover, the patient’s course of
therapy was complicated by pneumonia, which along
with infections from other encapsulated organisms,
may represent a possible side effect of the medication.
Further research, specifically, larger scale prospective
studies, are needed to better assess the degree of
efficacy and safety of eculizumab for gemcitabineinduced TMA.
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